News

Hemispherx Biopharma’s (Hemispherx) board of directors has approved up to $4.4m for full engineering studies, capital improvements, system upgrades, and introduction of building management systems to enhance production

The FDA has approved Sirion Therapeutics’ (Sirion) New Drug Application for Zirgan (ganciclovir ophthalmic gel) 0.15% as a treatment for acute herpetic keratitis (dendritic ulcers). The FDA granted

BioSpecifics Technologies (BioSpecifics) has reported that the Arthritis Advisory Committee appointed by the FDA has unanimously recommended that Xiaflex (collagenase clostridium histolyticum), a new orphan-designated, biologic, be granted

QIAGEN has acquired additional licenses from Roche and Idaho Technology related to the use of instrumentation and reagents for PCR-based molecular testing. Reportedly, the agreements cover thermal cycler

The FDA has indicated that CEL-SCI can proceed with its first clinical trial to evaluate the effect of its investigational LEAPS-H1N1 treatment on the white blood cells of

Coughlin Stoia Geller Rudman & Robbins (Coughlin Stoia) has filed a class action in the US District Court for the Eastern District of Pennsylvania on behalf of purchasers

Oculus Innovative Sciences (Oculus) has entered into a new strategic partnership with V&M Industries for non-exclusive rights to market Microcyn-based skin and wound care over-the-counter products in the

Mylan has reported that its Indian subsidiary, Matrix Laboratories has received tentative approval from the FDA under the President’s Emergency Plan for AIDS Relief (PEPFAR) for its New

AEterna Zentaris has reported that Keryx, its partner and licensee for perifosine in the North American market, has received orphan-drug designation for the compound from the FDA for